期刊文献+

尿激酶型纤溶酶原激活物受体与肿瘤 被引量:4

下载PDF
导出
摘要 尿激酶型纤溶酶原激活物受体(uPAR)是缺乏跨膜及胞浆部分的单链膜糖蛋白受体,通过糖基磷脂酰肌醇(GPI)锚定于细胞表面,在人体内广泛分布.
作者 徐霞 彭黎明
出处 《肿瘤》 CAS CSCD 北大核心 2003年第1期81-83,共3页 Tumor
  • 相关文献

参考文献20

  • 1[1]Andreasen PA, Kjoler L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: A review [J].Int J Cancer, 1997,72:l
  • 2[2]Bell WR. The fibrinolytic system in neoplasia [J]. Semin Thromb Hemost, 1996,22:459
  • 3[3]Dear AE, Medcalf RL. The urokinase-type-plasminogen-activator receptor(CD87) is a pleiotropic molecule [J]. Eur J Biochem, 1998,252:185
  • 4[4]Ossowski L, Aguirre-Ghiso .JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth [J]. Curr Opin Cell Biol,2000,12:613
  • 5[5]Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis:prognostic relevance and target for therapy [J]. Thromb Hemost,1997,78:285
  • 6[6]Huang S, New L, Pan ZX, et al. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38α mitogenactivated protein kinase activity [J]. J Biol Chem,2000,275:12266
  • 7[7]Del Vecchio S, Stoppelli MP, Carriero MV, et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels[J]. Cancer Res,1993,53:3198
  • 8[8]Jard M, Ingl s-Esteve J, Burgal M, et al. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells[J]. Thromb Hemost, 1996,76:1009
  • 9[9]Petro GD, Tavian D, Copeta A, et al. Expression of urokinase-type plasminogen activator (uPA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma [J]. Cancer Res,1998,58:2234
  • 10[10]Duggan C, Maguire T, Mcdermott E, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer[J]. Int J Cancer 1995,61:597

同被引文献45

  • 1[1]Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries[J]. Nature Medicin, 1996, 2:299-305.
  • 2[2]Szardenings M, Tornroth S, Mutulis F, et al. Phages display selection on whole cells yield a peptides specific for melanocortin receptor I[J]. J Bio Chem, 1997, 272:27943-27948.
  • 3[4]范郎娣.卵巢癌临床与病理[M].天津:天津科学技术出版社,1993.153-164.
  • 4[5]Ossowski L, Aguirre-ghiso JA. Urokinase receptor and integrin partnership:coordination of signaling for cell adhesion,migration and growth [J]. Curr Opin Cell Biol,2000,12: 613.
  • 5[6]Andreasen PA, Egelund R , Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis [J]. Cell Mol Life Sci, 2000, 57:25.
  • 6[7]Preissener KT, Knase SM, May AE. Urokinase receptor: a molecular organizer in cellular communication [J]. Curr Opin CHl Biol, 2000, 12:621.
  • 7[8]Borgfildt C, Hansson SR, Gustavsson B , et al. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plaseminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1)[J].Int Cancer, 2001,92(4):479-502.
  • 8Gerstein ES. Shcherbakov AI, Kazmin AI, et al. Urokinase and tissue type plasminogen activators and their typ-1 inhibitor(PAI-1) in gastric cancer[J]. Vopr Onkol. 2003, 49(2): 165-169.
  • 9Horn LC, Pipping S, Raptis G. et al. Clinical relevance of urokinase type plasminogen activator and its inhibitor type I(PAI-1) in squamous cell carainoma of the uterine cervix[J].Aust J Obstet Gynaecol, 2002, 42(42): 383-386.
  • 10Konno H, Abe J, Kaneko T. et al. Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer [J].Cance Res.2001,92(5): 516-523.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部